Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

NR2F6 has been proposed as an alternative cancer immune checkpoint in the effector T cell compartment. However, a realistic assessment of the in vivo therapeutic potential of NR2F6 requires acute depletion.

Source: Cell Communication and Signaling - January 14, 2020 Category: Molecular Biology Authors: Victoria Klepsch, Maria Pommermayr, Dominik Humer, Natascha Brigo, Natascha Hermann-Kleiter and Gottfried Baier Tags: Research Source Type: research